**Core Concept**
Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder characterized by proximal muscle pain and stiffness, primarily affecting individuals over the age of 50. It is associated with inflammation of the shoulder and hip joints, and systemic symptoms such as fatigue and weight loss.

**Why the Correct Answer is Right**
The correct answer is based on the fact that PMR is often treated with low-dose corticosteroids, which are effective in reducing inflammation and improving symptoms. The typical dose of prednisolone used to treat PMR is between 15-20 mg/day, and the response to treatment is usually rapid, with significant improvement in symptoms within 2-4 weeks. This is in contrast to other inflammatory conditions, such as giant cell arteritis, which may require higher doses of corticosteroids and more aggressive treatment.

**Why Each Wrong Option is Incorrect**
**Option A:** While PMR is often associated with giant cell arteritis, the two conditions have different treatment approaches and require careful distinction.
**Option B:** Methotrexate is a disease-modifying anti-rheumatic drug (DMARD) used in the treatment of rheumatoid arthritis and other autoimmune disorders, but it is not the first-line treatment for PMR.
**Option C:** Hydroxychloroquine is an antimalarial drug used in the treatment of lupus and other autoimmune disorders, but it is not effective in treating PMR.

**Clinical Pearl / High-Yield Fact**
PMR is a classic example of an "overlap syndrome," where patients may exhibit symptoms of both PMR and giant cell arteritis. A careful clinical evaluation and diagnostic workup are essential to differentiate between these two conditions and guide appropriate treatment.

**Correct Answer: C. Methotrexate is a disease-modifying anti-rheumatic drug (DMARD) used in the treatment of rheumatoid arthritis and other autoimmune disorders, but it is not the first-line treatment for PMR.